Haploid construction method based on low-concentration fetal free DNA
Through the dual-wheel magnetic bead screening and bioinformatic screening process combined with UMI molecular tags, the problem of low screening efficiency and accuracy of fetal free DNA fragments is solved, and the accurate construction of fetal haplotypes is achieved, and the accuracy of non-invasive prenatal detection is improved. and specificity.
Patent Information
- Application Number
- CN202411459089.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
AI Technical Summary
In the prior art, the screening efficiency and accuracy of fetal free DNA fragments are low, and the operation is complicated and long, resulting in insufficient accuracy and specificity of detection of non-invasive prenatal recessive genetic disease.
Two-wheel magnetic bead screening combined with the bioinformatic screening process was used to obtain DNA fragments of the target length range, and the sample raw DNA information was labeled through UMI molecular tags, reducing PCR or sequencing errors and improving the accuracy of haplotype construction.
It realizes the accurate and rapid construction of fetal haplotypes, improves the accuracy and specificity of detection, reduces maternal background interference, and ensures efficient non-invasive prenatal detection.
Smart Images

Figure CN119040438A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a monomer type construction method based on low-concentration fetal free DNA. Background Art
[0002] The difficulty of non-invasive prenatal detection of fetal monogenic diseases is affected by their inheritance mode: new mutations or dominant mutations from the father are not interfered by the mother's own mutation background, so the fetus's own genotype can be determined by simply detecting the presence or absence of gene mutation signals. Therefore, more sensitive digital PCR or target region capture sequencing methods are used to achieve this; while for recessively inherited monogenic diseases, identifying whether it is the fetus' own mutation type under the maternal background requires high fetal concentration, experimental design, and sensitivity and specificity of analysis. For recessively inherited non-invasive monogenic disease detection, it is usually necessary to construct the haplotype information of the father and mother in advance, and use the haplotype module to increase the amount of available information. The genetic situation of a single site can be determined by the significant difference between the fetal-specific (paternal allele mutation) and the site counts on the same haplotype, and the significant difference between the two different maternal bases (maternal allele mutation and normal allele base) and the site counts on the same haplotype. The above-mentioned haplotype method has been widely used for non-invasive prenatal testing. However, due to the low content of fetal free DNA in maternal peripheral blood and the preference of probes in capturing and amplifying target region DNA, the accuracy of haplotype construction for some fetuses cannot be guaranteed. Optimizing the technical process of fetal haplotype construction and establishing a haplotype construction method for low-concentration fetal free DNA are the keys to achieving more accurate non-invasive prenatal testing. To this end, this patent proposes an accurate and effective haplotype construction method based on low-concentration fetal free DNA.
[0003] Beijing Maikino Gene Technology Co., Ltd. has developed a non-diagnostic method and probe design method for detecting PAH gene mutations. Genomic DNA is obtained from the white blood cells of the parents of the fetus to be tested; a second-generation sequencing library is formed based on the genomic DNA; free DNA is obtained from the plasma of pregnant women; a free DNA whole genome library is formed based on the free DNA; the second-generation sequencing library and the free DNA whole genome library are hybridized by probe capture to form a capture library; the capture library is subjected to high-throughput sequencing to obtain the original sequencing data; the original sequencing data is processed to obtain clean data; the genotype of the fetal PAH gene is determined based on the clean data. High accuracy and low cost. However, Beijing Maikino's probe design method is relatively traditional, and the probe capture area is small, 1Mb upstream and downstream of the pathogenic gene, and the coverage range is narrow, resulting in a small number of effective sites for fetal haplotype typing in pregnant women's plasma, and reduced sensitivity and specificity. Low-concentration fetal free DNA is not enriched. UMI (Unique Molecular Identifiers) molecular tags are not added to restore the original DNA molecular information of the sample, so its detection specificity is low.
[0004] Therefore, there is an urgent need to provide a monomer type construction method based on low-concentration fetal free DNA to improve detection accuracy and specificity. Summary of the invention
[0005] In view of the shortcomings of the prior art and actual needs, the present invention provides a method for constructing a haplotype based on low-concentration fetal free DNA, which solves the problems of low efficiency and accuracy in screening fetal free DNA fragments in the prior art, complex operation and long time, and can accurately and quickly construct a fetal haplotype.
[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a method for constructing a haplotype based on low-concentration fetal free DNA, the method comprising: obtaining free DNA fragments by double-round magnetic bead screening, constructing a cfDNA library by mixing the free DNA fragments and UMI molecular tags, capturing the blocked cfDNA library with probes, purifying the probe capture products, sequencing to obtain sequencing data, further screening the sequencing data to obtain the final free DNA fragments, and obtaining the fetal haplotype by sequence analysis of the final free DNA fragments.
[0008] The present invention uses a double-round magnetic bead screening process combined with a bioinformatics screening process to obtain DNA fragments in a target length range, thereby achieving the purpose of enriching fetal free DNA. Compared with pure experimental methods and pure bioinformatics methods, the fetal free DNA is more efficient and the target length range is more accurate. At the same time, the present invention introduces UMI molecular tags to mark the original DNA molecular information of the sample to reduce base errors introduced by PCR or sequencing errors, thereby greatly improving the accuracy of fetal haplotype construction.
[0009] Preferably, the two-round magnetic bead screening includes a first round of screening using magnetic beads with a volume of 0.6-0.8 times the volume of fetal free DNA fragments, and a second round of screening using magnetic beads with a volume of 1.0-1.4 times the volume of fetal free DNA fragments.
[0010] The specific point values among the above 0.6-0.8 times can be selected as 0.6 times, 0.62 times, 0.64 times, 0.68 times, 0.7 times, 0.74 times, 0.78 times, 0.8 times, etc.
[0011] The specific point values among the above 1.0-1.4 times can be selected as 1.0 times, 1.04 times, 1.06 times, 1.08 times, 1.1 times, 0.14 times, 0.18 times, 1.2 times, 1.3 times, 1.35 times, 1.4 times, etc.
[0012] Preferably, the nucleic acid sequence of the UMI molecular tag includes the sequence shown in SEQ ID NO.1-SEQ ID NO.20.
[0013] SEQ ID NO.1:TAATCG.
[0014] SEQ ID NO.2:TATGAC.
[0015] SEQ ID NO.3:TATCCA.
[0016] SEQ ID NO.4: TACTTC.
[0017] SEQ ID NO.5: TTACGA.
[0018] SEQ ID NO.6:TTGTCA.
[0019] SEQ ID NO.7:TTCACT.
[0020] SEQ ID NO.8:TTCTGG.
[0021] SEQ ID NO.9:TGAGCA.
[0022] SEQ ID NO.10: TGTATC.
[0023] SEQ ID NO.11:TGTTAG.
[0024] SEQ ID NO.12:TGTCGT.
[0025] SEQ ID NO.13:TGCCAC.
[0026] SEQ ID NO.14: TCAGGC.
[0027] SEQ ID NO.15: TCTTGA.
[0028] SEQ ID NO.16:TCTGCT.
[0029] SEQ ID NO. 17: TCGACC.
[0030] SEQ ID NO.18:TCGCAG.
[0031] SEQ ID NO. 19: TCCTAT.
[0032] SEQ ID NO. 20: GAATAC.
[0033] Preferably, the nucleic acid sequence of the probe includes the sequence shown in SEQ ID NO.21-SEQ ID NO.25.
[0034] In the present invention, the probes are designed using thalassemia-related genes (HBA and HBB genes) as an example. It can be understood that probes designed for other genes are within the protection scope of the present invention.
[0035] SEQ ID NO.21(chr11:2262418-2262518):
[0036] TTACTTAATAATAATGTATA-CTATTGGTTCATTAACCATGATAATGTTCCATACCAATGTAAGATGGTGATAATAGGACAAACTGGGTGTGGGGTTTAT.
[0037] SEQ ID NO.22(chr11:2269062-2269162):
[0038] GCAGTCTGTTAACTGGATCTGACGAGCAAGCAGGGGGAAAGTACTCTGG-AGCCCCAAGTAAGGCACACGAGCCAGGCTGGGAGATAAATTCCACGAAGCT.
[0039] SEQ ID NO.23(chr11:2270526-2270626):
[0040] TGAAGAGCTGTTTAGCTAAAGGGAAGCCCCACATCCGGGA-GTGTGT GCCCTGGGGGACACACAGCAAATGACTGACAAGGAGGAACAGAAGGCA GCCTC.
[0041] SEQ ID NO.24(chr11:2276689-2276789):
[0042] TTC-AATGGAAATTAAAATGCTCTAGGATAGTCAAAATAATTTAGGA AAATTATTTTCTGGTCACTATCTGATTTCACTGATATGTTACTATATATTT AC.
[0043] SEQ ID NO.25(chr11:2277158-2277258):
[0044] CGGTACTGTTGCCATTTGGGGATGTAGCTCCTGTGTGGGGGCTGGTCTGTGCACCAGGGAGGTTTAGCA-GGGTGTGCTCCAGTTGTGACAACTAAC AAT.
[0045] Preferably, the further screening criterion is to select free DNA fragments whose sequence ends are G or C for sequence analysis.
[0046] Preferably, the final fetal free DNA fragments are 140-165 bp in length.
[0047] The specific point values in the above 140-165bp can be selected as 140bp, 145bp, 148bp, 150bp, 155bp, 160bp, 162bp, 165bp, etc.
[0048] In a second aspect, the present invention provides a UMI molecular tag for constructing a haplotype, wherein the nucleic acid sequence of the UMI molecular tag includes a sequence shown in SEQ ID NO.1-SEQ ID NO.20.
[0049] In a third aspect, the present invention provides a probe for constructing a haplotype, wherein the nucleic acid sequence of the probe includes the sequence shown in SEQ ID NO.21-SEQ ID NO.25.
[0050] In a fourth aspect, the present invention provides a kit for constructing a haplotype, wherein the kit contains the UMI molecular tag described in the second aspect and / or the probe described in the third aspect.
[0051] In a fifth aspect, the present invention provides use of the haplotype construction method of the first aspect, the UMI molecular tag of the second aspect, the probe of the third aspect, or the kit of the fourth aspect in constructing haplotypes for purposes other than disease diagnosis or treatment.
[0052] Compared with the prior art, the present invention has the following beneficial effects:
[0053] (1) The present invention can reduce maternal background and increase the concentration of fetal free DNA. The present invention uses a double-round magnetic bead screening process combined with a bioinformatics screening process to obtain DNA fragments in a target length range to achieve the purpose of enriching fetal free DNA. Then, based on the fact that the frequency of GC at the terminal base of the fetal free DNA sequence is higher, a sequence end feature screening algorithm is used to further enrich fetal free DNA. Compared with pure experimental methods and pure bioinformatics methods, the fetal free DNA enrichment efficiency is higher and the target length range is more accurate. At the same time, the present invention introduces UMI molecular tags to mark the original DNA molecular information of the sample to reduce base errors introduced by PCR or sequencing errors, thereby greatly improving the accuracy of fetal haplotype construction;
[0054] (2) The present invention identifies SNP sites with high heterozygosity in the target gene region of a common genetic disease, designs capture probes corresponding to the base deletion at the SNP site according to the SNP site sequence, reduces the bias of allele capture, and designs nearly 3,000 evenly distributed SNP sites within 3M upstream and downstream of the target region, ensuring that each fetus can obtain thousands of effective sites for fetal haplotype construction, which can effectively improve the accuracy;
[0055] (3) The DNA ligase and DNA polymerase of the present invention are placed in one reaction, so that the single-strand circularization and rolling circle amplification processes can be carried out in the same reaction, saving operation steps, greatly shortening the experimental process from library preparation to machine operation, and realizing accurate and efficient fetal haplotype construction. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 Construct a flow chart for fetal haplotypes. DETAILED DESCRIPTION
[0057] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.
[0058] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0059] In order to more easily understand the present invention, some terms are first defined. As used in the present invention, unless otherwise defined, all technical terms and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. All patents and publications mentioned in the present invention are incorporated into the present invention in their entirety by reference.
[0060] The term "cfDNA" refers to cell-free DNA.
[0061] The term "cffDNA" refers to cell-free fetal DNA.
[0062] The term "UMI" refers to Unique Molecular Identifiers, unique molecular tags.
[0063] Example 1
[0064] Improve confirmation of fetal concentration fragment range.
[0065] Based on the phenomenon that the free DNA from the fetus in maternal peripheral blood is shorter than the free DNA from the mother, the purpose of enriching fetal DNA can be achieved by obtaining free DNA with short fragments in the target length range. In order to confirm the changes in the concentration of fetal DNA corresponding to peripheral blood free DNA of different lengths, the sequence length (readslength) of the existing male fetal samples was divided into bins for analysis. The specific detection process is as follows:
[0066] (1) Peripheral blood was collected from pregnant volunteers, and cfDNA was extracted from plasma according to Qiagen's "QIAamp Circulating Nucleic Acid Handbook".
[0067] (2) cfDNA library construction: using iGeneTech's IGT TM FastLibraryPrepKitv2.0 was used for library construction. The main steps included: end repair and A-tailing, UMI molecular tag (SEQ ID NO.1-SEQ ID NO.20) connection and purification, and then PCR amplification to obtain cfDNA library.
[0068] (3) Target region probe capture: using iGeneTech's TargetSeq The Hyb&WashKit v2.0 kit is operated according to the instructions to block the cfDNA library before hybridization to obtain a blocked cfDNA library; then the probes for the probe capture region of the present invention are prepared into a probe mixture; and rapid hybridization capture is performed with the blocked cfDNA library.
[0069] (4) Target region enrichment: The probe capture product was eluted using CapBeads to obtain the captured target sequence, and the captured target sequence was amplified by PCR to obtain the enriched target sequence. The PCR amplification system was: 24 μL of captured target sequence, 5 μL of PostPCR Master Mix, and 1 μL of PostPCR Primer. The reaction conditions were: pre-denaturation at 95°C for 1 min; 14 cycles (denaturation at 98°C for 20 s; annealing at 60°C for 30 s; extension at 72°C for 30 s); extension at 72°C for 5 min. The PCR product was purified using Beckman Coulter's Agencourt AM Pure XP Kit to obtain the product to be sequenced.
[0070] (5) Sequencing: Sequencing is performed on the BGI MGISEQ-200 high-throughput sequencer. Before sequencing, the constructed cfDNA library needs to be fully mixed with the DNB preparation buffer; after high-temperature denaturation and low-temperature annealing, the oligonucleotides are bound to the cfDNA library; the annealing products are gently pipetted and mixed with the DNA ligase and polymerase mixture and buffer; at low temperatures, the cfDNA undergoes circularization and rolling circle amplification simultaneously; the rolling circle amplification products are terminated with the DNB termination buffer to obtain DNA nanoballs for sequencing.
[0071] (6) Result analysis: Each length gradient threshold was set to screen the read length, and the fetal DNA concentration obtained under different screening coefficients was further statistically analyzed, as shown in Table 1 below. The fetal DNA concentration was calculated by fetal-specific allele readings, and the readings of the alleles of the sites where the parents were homozygous but had different alleles or the father was heterozygous and the mother was homozygous were calculated. The calculation method was as follows: f = S2p / S(p+q). Among them, f is the fetal DNA concentration, p is the allele count of the fetus's inherited father's haplotype, q is the allele count shared by the mother and the fetus, S2p is the sum of 2 times the allele counts of the fetus's inherited father's haplotype, and S(p+q) is the sum of all the allele counts of the fetus's inherited father's haplotype plus the allele counts shared by the mother and the fetus. The enrichment efficiency of the fetal free DNA concentration is shown in Table 1.
[0072] Table 1
[0073] Read length Fetal DNA concentration (%) Average enrichment efficiency (fold) ≤135bp 12.05 1.25 ≤140bp 14.09 1.46 ≤145bp 13.65 1.41 ≤150bp 13.68 1.42 ≤155bp 14.1 1.46 ≤160bp 13.71 1.42 ≤165bp 13.76 1.43 ≤170bp 12.88 1.33 allreads 9.62 1
[0074] The results showed that the enrichment efficiency of fetal free DNA was highest in the free DNA fragment length range of 140-165bp.
[0075] Example 2
[0076] The ratio of magnetic beads input in double-round magnetic bead enrichment is determined.
[0077] (1) Samples: Peripheral blood was collected from pregnant volunteers, and free DNA was extracted from the plasma using Qiagen's "QIAamp Circulating Nucleic Acid Handbook".
[0078] (2) Construction of maternal plasma library: The fragmented DNA was end-repaired and A-tailed, linker-ligated and purified, and finally amplified and purified by PCR to obtain the cfDNA library.
[0079] (3) Enrichment of fetal concentration: Set the magnetic bead ratio gradients of the library obtained in the previous step to enrich short fragments to obtain the enriched library: add the AmpureXPBeads (Agencourt) magnetic beads of the first round of magnetic bead ratio volume to the free DNA library obtained in the previous step, incubate for 5 minutes, place on the magnetic stand for adsorption for 3 minutes, take the supernatant, and discard the magnetic beads; then add the magnetic beads of the second round of magnetic bead ratio supernatant volume, incubate for 5 minutes, place on the magnetic stand for adsorption for 3 minutes, remove the supernatant, and keep the magnetic beads. After washing twice with anhydrous ethanol, dissolve the free DNA fragments back into 30μL of nuclease-free water to obtain the library. Add the appropriate amount of magnetic beads to the centrifuge tube according to Table 2 below. The results of the magnetic bead enrichment ratio are shown in Table 3. (0.7× means that the volume of magnetic beads is 0.7 times the volume of the extracted free DNA.)
[0080] Table 2
[0081] Experiment number The first round of magnetic beads ratio Second round of magnetic bead ratio DNA fragment length (bp) 1 0.7× 1.2× 155±15 2 0.8× 1.0× 155±10 3 0.6× 1.4× 155±20 4 0.5× 1.2× 170±20 5 0.9× 1.2× 145±15 6 0.7× 0.8× 165±5 7 0.7× 1.6× 135±30
[0082] The results showed that in Experiment 1, the DNA fragments screened according to the double-round magnetic bead screening at 0.7× and 1.2× were closest to the target region DNA fragment length range. In Experiments 4-6, the first-round magnetic bead ratio or the second-round magnetic bead ratio was not within the range precisely controlled by the present invention, and as a result, the DNA fragment length was not within the optimal range of 140-165 bp.
[0083] Example 3
[0084] Construction of fetal haplotypes.
[0085] (1) Samples: Free DNA was extracted from the plasma of pregnant volunteers with low fetal free DNA concentration (<10%) using Qiagen's "QIAamp Circulating Nucleic Acid Handbook". Genomic DNA was extracted from paternal and maternal peripheral blood using an extraction kit.
[0086] (2) Construction of plasma free DNA library of volunteer pregnant women and paternal and maternal genomic DNA library: refer to Example 1.
[0087] (3) Enrichment of fetal concentration: Add 0.7 times the volume of Ampure XPBeads (Agencourt) magnetic beads to the free DNA library obtained in the previous step, incubate for 5 minutes, place on a magnetic stand for adsorption for 3 minutes, remove the supernatant, and discard the magnetic beads; then add 1.2 times the volume of the supernatant magnetic beads, incubate for 5 minutes, place on a magnetic stand for adsorption for 3 minutes, remove the supernatant, and keep the magnetic beads. After washing twice with anhydrous ethanol, dissolve the free DNA fragments back into 30 μL of nuclease-free water to obtain the library.
[0088] (4) Targeted capture and sequencing are the same as in Example 1.
[0089] (5) Result analysis: After obtaining the free DNA sequencing results, the cffDNA enrichment algorithm based on sequence motif characteristics and fragment length was combined to further improve the efficiency and accuracy of fragment screening. Then, according to the comparison of the reference genome sequence, the effective sites are screened and the selected effective sites are corrected according to the original DNA molecular sequence information of the UMI tag, the base error information introduced by PCR amplification sequencing errors is excluded, and the available effective sites are determined. The effective sites must meet the following requirements: paternal homozygosity, maternal heterozygosity or paternal heterozygosity, maternal homozygosity; the fetal effective sites are screened according to the site frequency and the fetal haplotype is constructed. The screening rules are as follows: 1) The sites of paternal homozygosity and maternal heterozygosity are set to AA and AB. When the fetus inherits the maternal A site, the frequency of site A increases and the frequency of site B decreases; when the B site is inherited, the frequencies of sites A and B remain unchanged, both 50%; all these two types of sites constitute a haplotype of the fetus derived from the mother; 2) The sites of paternal heterozygosity and maternal homozygosity are set to AB and AA. When the fetus inherits the paternal A site, the frequency of site A is 100% and the frequency of site B is 0; when the B site is inherited, the frequency of site B will change and increase with the increase of fetal concentration. All these two types of sites constitute a haplotype of the fetus derived from the father; the fetal haplotype construction process is as follows Figure 1 shown.
[0090] (6) After the fetal haplotype based on low-concentration fetal free DNA is constructed, the disease status of the fetus can be further determined based on the comparison of the parental haplotype sites and the pathogenicity of the parental haplotypes. The fetal concentration enrichment efficiency and typing results are shown in Table 3.
[0091] (7) General library construction scheme: Collect peripheral blood from pregnant volunteers and extract cfDNA from plasma; obtain cfDNA library by end repair, A-tailing, purification, and introduction of index operation (without UMI tag); use conventional thalassemia HBA / HBB gene region probes to quickly hybridize and capture the closed cfDNA library; elute the probe capture product using Cap Beads to obtain the captured target sequence, PCR amplify the captured target sequence, and purify it; fully mix the constructed cfDNA library with the clamp primer and DNA ligase system, denature, anneal, digest the clamp primer, and purify it, then add the polymerase mixture for rolling circle amplification to obtain DNA nanoballs for sequencing. Sequencing was performed on the BGISEQ-200 high-throughput sequencer, and then fetal haplotype construction and analysis were performed according to direct statistical effective sites.
[0092] The number of effective sites that can be used for fetal haplotype construction obtained by different library construction schemes was compared using the general library construction scheme and the enrichment library construction scheme of the present invention. Experiments 1-7 are library construction methods for cffDNA enrichment using different magnetic bead screening ratios in Example 2, and experiments 8-12 are library construction methods for cffDNA enrichment using the optimal magnetic bead screening ratio of the present invention (screening using magnetic beads with 0.7 times the volume of fetal free DNA fragments in the first round, and screening using magnetic beads with 1.2 times the volume of fetal free DNA fragments in the second round) combined with the bioinformatics allele algorithm.
[0093] Table 3
[0094]
[0095] From the comparison of the results of enriched library construction and general library construction, it can be seen that enriched library construction can increase the proportion of cffDNA, thereby increasing the number of effective sites that can be used to construct fetal haplotypes, and further improving the accuracy of construction. From Experiments 1 to 7, it can be seen that the volume of magnetic beads was not precisely controlled in the first and second rounds, and the cffDNA enrichment ratio (enriched / conventional) could only reach 1.4. From Experiments 8 to 12, it can be seen that when the first round used magnetic beads with 0.7 times the volume of fetal free DNA fragments for screening, and the second round used magnetic beads with 1.2 times the volume of fetal free DNA fragments for screening, the method of the present invention can achieve a cffDNA enrichment ratio (enriched / conventional) of 1.70, which is more efficient in enriching fetal free DNA than pure experimental methods and pure bioinformatics methods, and the target length range is more accurate.
[0096] In summary, the present invention uses a double-round magnetic bead screening process combined with a bioinformatics allele screening process to obtain DNA fragments in a target length range, thereby achieving the purpose of enriching fetal free DNA. Compared with pure experimental methods and pure bioinformatics methods, the fetal free DNA is more efficient and the target length range is more accurate. At the same time, the present invention introduces UMI molecular tags to mark the original DNA molecular information of the sample to reduce base errors introduced by PCR or sequencing errors, thereby greatly improving the accuracy of fetal haplotype construction.
[0097] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A method for constructing a haplotype based on low-concentration fetal free DNA, characterized in that: The haplotype construction method comprises: Double-round magnetic bead screening was used to obtain free DNA fragments. The free DNA fragments and UMI molecular tags were mixed to construct a cfDNA library. The closed cfDNA library was captured using probes, the probe capture products were purified, and sequencing was performed to obtain sequencing data. The sequencing data was further screened to obtain the final free DNA fragments. The final free DNA fragments were sequenced to obtain the fetal haplotype.
2. The method for constructing a haplotype according to claim 1, wherein: The double-round magnetic bead screening includes a first round of screening using magnetic beads with a volume of 0.6-0.8 times the volume of fetal free DNA fragments, and a second round of screening using magnetic beads with a volume of 1.0-1.4 times the volume of fetal free DNA fragments.
3. The method for constructing a haplotype according to claim 1 or 2, wherein: The nucleic acid sequence of the UMI molecular tag includes the sequence shown in SEQ ID NO.1-SEQ ID NO.
20.
4. The method for constructing a haplotype according to any one of claims 1 to 3, characterized in that: The nucleic acid sequence of the probe includes the sequences shown in SEQ ID NO.1-SEQ ID NO.
64.
5. The method for constructing a haplotype according to any one of claims 1 to 4, characterized in that: The further screening criteria are to select free DNA fragments whose sequence ends are G or C for sequence analysis.
6. The method for constructing a haplotype according to any one of claims 1 to 5, characterized in that: The final free DNA fragments have a length of 140-165 bp.
7. A UMI molecular tag for constructing a haplotype, characterized in that: The nucleic acid sequence of the UMI molecular tag includes the sequence shown in SEQ ID NO.1-SEQ ID NO.
20.
8. A probe for constructing a haplotype, characterized in that The nucleic acid sequence of the probe includes the sequences shown in SEQ ID NO.21-SEQ ID NO.
25.
9. A kit for constructing a haplotype, characterized in that The kit contains the UMI molecular tag of claim 7 and / or the probe of claim 8.
10. Use of the haplotype construction method according to any one of claims 1 to 5, the UMI molecular tag according to claim 7, the probe according to claim 8, or the kit according to claim 9 in constructing haplotypes for purposes other than disease diagnosis or treatment.
